Nitroimidazoles for the treatment of TB: Past, present and future

Future Medicinal Chemistry

Volumn 3, Issue 11, 2011, Pages 1427-1454

  Mukherjee, Tathagata ^a   Boshoff, Helena ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; 5 NITROIMIDAZOLE DERIVATIVE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; CGI 17341; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; IMIDAZO[2,1 B]OXAZOLE DERIVATIVE; ISONIAZID; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZO[2,1 B]OXAZINE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; ORNIDAZOLE; PYRAZINAMIDE; RIFAMPICIN; SARACATINIB; SECNIDAZOLE; TINIDAZOLE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; NITROIMIDAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS, PULMONARY;

EID: 80052393888     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.90     Document Type: Review

References (118)

1. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tuberculosis incidence and their determinants in 134 countries. Bull. World Health Organ. 87(9), 683-691 (2009).
2. Young D, Dye C. The development and impact of tuberculosis vaccines. Cell 124(4), 683-687 (2006). (Pubitemid 43261442)
3. Jordan TS, Davies PD. Clinical tuberculosis and treatment outcomes. Int. J. Tuberc. Lung Dis. 14(6), 683-688 (2010).
4. Voogd CE. On the mutagenicity of nitroimidazoles. Mutat. Res. 86(3), 243-277 (1981). (Pubitemid 11063716)
5. Roe FJ. Metronidazole: review of uses and toxicity. J. Antimicrob. Chemother. 3(3), 205-212 (1977). (Pubitemid 8097315)
6. Roe VA. Antimicrobial agents: pharmacology and clinical application in obstetric, gynecologic, and perinatal infections. J. Obstet. Gynecol. Neonatal Nurs. 28(6), 639-648 (1999).
7. Schneider J. Treatment of giardiasis (lambliasis) by metronidazole. Bull. Soc. Pathol. Exot. Filiales 54, 84-95 (1961).
8. Rodriques Coura J, De Castro SL. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz. 97(1), 3-24 (2002). (Pubitemid 135746197)
9. Veldhuyzen Van Zanten SJ, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. CMAJ 156(11), 1565-1574 (1997).
10. Barry CE 3rd, Boshoff HI, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10(26), 3239-3262 (2004). (Pubitemid 39276613)
11. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38(9), 2054-2058 (1994). (Pubitemid 24278800)
12. Via LE, Lin PL, Ray SM et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76(6), 2333-2340 (2008).
13. Barry CE 3rd, Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7(12), 845-855 (2009).
14. Young DB, Perkins MD, Duncan K, Barry CE 3rd. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest. 118(4), 1255-1265 (2008). (Pubitemid 351500418)
15. Cavalleri B, Ballotta R, Arioli V, Lancini G. New 5-substituted 1-alkyl-2- nitroimidazoles. J. Med. Chem. 16(5), 557-560 (1973).
16. Cavalleri B, Volpe G, Arioli V, Parenti F. Synthesis and biological activity of some 2-aminoimidazoles. Arzneimittelforschung 27(10), 1889-1895 (1977). (Pubitemid 8169232)
17. Schmid A, Schmid H. Pharmaco-toxicological mode of action of antimicrobial 5-nitroimidazole derivatives. Zentralbl Veterinarmed A 46(9), 517-522 (1999). (Pubitemid 129580915)
18. Sehgal RK, Agrawal KC. Novel Nitroimidazo[2,1-b] oxazole formation from reaction of 2,4(5)-dinitroimidazole with Oxiranes (1). J. Heterocyclic Chem. 16, 1499-1500 (1979).
19. Nagarajan K, Shankar RG, Rajappa S, Shenoy SJ, Costa-Pereira R. Nitroimidazole XXI 2,3-dihtdro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity. Eur. J. Med. Chern. 24, 631-633 (1989). (Pubitemid 20025798)
20. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37(2), 183-186 (1993). (Pubitemid 23046551)
21. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3(11), e466 (2006).
22. Denny WA, Palmer BD. The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Future Med Chem 2(8), 1295-1304 (2010).
23. Stover CK, Warrener P, Vandevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405(6789), 962-966 (2000). (Pubitemid 30435054)
24. Hof H. Antibacterial activities of the antiparasitic drugs nifurtimox and benznidazole. Antimicrob. Agents Chemother. 33(3), 404-405 (1989). (Pubitemid 19071982)
25. Jokipii L, Jokipii AMM. Comparative-evaluation of the 2-methyl-5-nitroimidazole compounds dimetridazole, metronidazole, secnidazole, ornidazole, tinidazole, carnidazole, and panidazole against Bacteroides-fragilis and other bacteria of the Bacteroides-fragilis group. Antimicrob. Agents Chemother. 28(4), 561-564 (1985). (Pubitemid 16236550)
26. Hof H, Stroder J. Antibacterial Activity of Go 10213, a Nitroimidazole Derivative. Antimicrob Agents Ch 29(5), 953-954 (1986). (Pubitemid 16118350)
27. Cavalleri B, Volpe G, Arioli V. Synthesis and biological activity of some vinyl-substituted 2-nitroimidazoles. J. Med. Chem. 20(5), 656-660 (1977). (Pubitemid 8095437)
28. Cavalleri B, Volpe G, Arioli V, Lancini G. Synthesis and biological activity of two metabolites of 1-methyl-5-(1-methylethyl)-2- nitro-1 H-imidazole, an antiprotozoal agent. J. Med. Chem. 20(11), 1522-1525 (1977). (Pubitemid 8209573)
29. Cavalleri B, Volpe G, Ripamonti A, Arioli V. 1-methyl-2-nitroimidazol-5- yl derivatives. IIIrd communication. Arzneimittelforschung 27(6), 1131-1134 (1977).
30. Kim P, Zhang L, Manjunatha UH et al. Structure-activity relationships of antitubercular nitroimidazoles. 1 Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J. Med. Chem. 52(5), 1317-1328 (2009).
31. Kim P, Kang S, Boshoff HI et al. Structure- activity relationships of antitubercular nitroimidazoles. 2 Determinants of aerobic activity and quantitative structure-activity relationships. J. Med. Chem. 52(5), 1329-1344 (2009).
32. Thompson AM, Blaser A, Anderson RF et al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4- (trifluoromethoxy)benzyl]oxy}-6,7-dihydro- 5H-imidazo[2, 1-b][1,3]oxazine (PA-824).J. Med. Chem. 52(3), 637-645 (2009).
33. Palmer BD, Thompson AM, Sutherland HS et al. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5H-imidazo[2, 1-b][1,3]oxazine (PA-824).J. Med. Chem. 53(1), 282-294 (2010).
34. Sutherland HS, Blaser A, Kmentova I et al. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J. Med. Chem. 53(2), 855-866 (2010).
35. Kmentova I, Sutherland HS, Palmer BD et al. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7- dihydro-5H-imidazo[2, 1-b] [1,3]oxazine (PA-824).J. Med. Chem. (2010).
36. Li X, Manjunatha UH, Goodwin MB et al. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4- (trifluoromethoxy) benzyloxy)-6,7-dihydro- 5H- imidazo[2,1-b][1,3]oxazines, analogues of PA-824 Bioorg. Med. Chem. Lett. 18(7), 2256-2262 (2008).
37. Bollo S, Nunez-Vergara LJ, Kang S et al. The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824 Bioorg. Med. Chem. Lett. 21(2), 812-817 (2011).
38. Singh R, Manjunatha U, Boshoff HI et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322(5906), 1392-1395 (2008). (Pubitemid 352775253)
39. Matsumoto M, Hashizume H, Tsubouchi H et al. Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis. Curr. Top. Med. Chem. 7(5), 499-507 (2007). (Pubitemid 46488290)
40. Sasaki H, Haraguchi Y, Itotani M et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3- dihydroimidazo[2,1- b]oxazoles. J. Med. Chem. 49(26), 7854-7860 (2006). (Pubitemid 46033674)
41. Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr. Med. Chem. 15(19), 1956-1967 (2008).
42. Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. 1 Mechanisms of action. J. Antimicrob. Chemother. 31(1), 9-20 (1993). (Pubitemid 23078062)
43. Edwards DI. Reduction of nitroimidazoles in vitro and DNA damage. Biochem. Pharmacol. 35(1), 53-58 (1986). (Pubitemid 16161362)
44. Perezreyes E, Kalyanaraman B, Mason RP. The reductive metabolism of metronidazole and ronidazole by aerobic liver-microsomes. Mol. Pharmacol. 17(2), 239-244 (1980). (Pubitemid 10125311)
45. Sealy RC, Swartz HM, Olive PL. Electron-spin resonance spin trapping - detection of superoxide formation during aerobic microsomal reduction of nitro-compounds. Biochem. Bioph. Res. Co. 82(2), 680-684 (1978). (Pubitemid 8350585)
46. Sisson G, Jeong JY, Goodwin A et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori rdxA plus (nitroreductase) gene. J. Bacteriol. 182(18), 5091-5096 (2000).
47. Thompson SA, Blaser MJ. Isolation of the Helicobacter-pylori reca gene and involvement of the reca region in resistance to low ph. Inf. Immun. 63(6), 2185-2193 (1995).
48. Yeung TC, Beaulieu BB, Mclafferty MA, Goldman P. Interaction of metronidazole with DNA-repair mutants of Escherichia-coli. Antimicrob. Agents Chemother. 25(1), 65-70 (1984).
49. Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. 2 Mechanisms of resistance. J. Antimicrob. Chemother. 31(2), 201-210 (1993). (Pubitemid 23092833)
50. Ragsdale SW. Pyruvate ferredoxin oxidoreductase and its radical intermediate. Chem. Rev. 103(6), 2333-2346 (2003).
51. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 14(1), 150-164 (2001). (Pubitemid 32096211)
52. Borst P, Ouellette M. New mechanisms of drug-resistance in parasitic protozoa. Ann. Rev. Microbiol. 49, 427-460 (1995).
53. Dunne RL, Dunn LA, Upcroft P, O'Donoghue PJ, Upcroft JA. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res. 13(4), 239-249 (2003). (Pubitemid 43225253)
54. Carlier JP, Sellier N, Rager MN, Reysset G. Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis. Antimicrob. Agents Chemother. 41(7), 1495-1499 (1997). (Pubitemid 27289674)
55. Mendz GL, Trend MA. Intracellular redox status and antibiotic resistance in enterogastric micro-aerophilic bacteria: evidence for the 'scavenging of oxygen' hypothesis. Redox Rep. 6(3), 179-181 (2001). (Pubitemid 32694481)
56. Rafii F, Wynne R, Heinze TM, Paine DD. Mechanism of metronidazole- resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. Fems Microbiol. Lett. 225(2), 195-200 (2003). (Pubitemid 38373389)
57. Mendz GL, Megraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol. 10(8), 370-375 (2002). (Pubitemid 34876798)
58. Goodwin A, Kersulyte D, Sisson G, Van Zanten SJOV, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28(2), 383-393 (1998). (Pubitemid 28182260)
59. Kwon DH, Osato MS, Graham DY, El-Zaatari FaK. Quantitative RT-PCR analysis of multiple genes encoding putative metronidazole nitroreductases from Helicobacter pylori. Int. J. Antimicrob. Agents 15(1), 31-36 (2000). (Pubitemid 30336368)
60. Sisson G, Goodwin A, Raudonikiene A et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 46(7), 2116-2123 (2002). (Pubitemid 34665905)
61. Hoffman PS, Goodwin A, Johnsen J, Magee K, Veldhuyzen SJO, Vanzanten SJOV. Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: Repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J. Bacteriol. 178(16), 4822-4829 (1996). (Pubitemid 26321281)
62. Smith MA, Edwards DI. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter-pylori to nitroheterocyclic drugs. J. Antimicrob. Chemother. 35(6), 751-764 (1995).
63. Lim A, Eleuterio M, Hutter B, Murugasu-Oei B, Dick T. Oxygen depletion-induced dormancy in Mycobacterium bovis BCG. J. Bacteriol. 181(7), 2252-2256 (1999). (Pubitemid 29164981)
64. Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int. J. Parasitol. 29(2), 199-212 (1999).
65. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob. Agents Chemother. 43(7), 1533-1541 (1999). (Pubitemid 29331224)
66. Hughes NJ, Chalk PA, Clayton CL, Kelly DJ. Identification of carboxylation enzymes and characterization of a novel 4-subunit pyruvate-flavodoxin oxidoreductase from Helicobacter-pylori. J. Bacteriol. 177(14), 3953-3959 (1995).
67. Baughn AD, Garforth SJ, Vilcheze C, Jacobs WR Jr. An anaerobic-type a-ketoglutarate ferredoxin oxidoreductase completes the oxidative tricarboxylic acid cycle of Mycobacterium tuberculosis. PLoS Pathog. 5(11), e1000662 (2009).
68. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2(3), 215-218 (2009).
69. Boshoff HI, Barry BC. Is the mycobacterial cell wall a hopeless drug target for latent tuberculosis? Drug Discov. Today Dis. Mech. 3, 237-245 (2006). (Pubitemid 44382362)
70. Manjunatha UH, Boshoff H, Dowd CS et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103(2), 431-436 (2006). (Pubitemid 43122418)
71. Boshoff HI, Barry CE 3rd. Tuberculosis - metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 3(1), 70-80 (2005). (Pubitemid 40028470)
72. Rao SP, Alonso S, Rand L, Dick T, Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105(33), 11945-11950 (2008).
73. Rhee KY, Erdjument-Bromage H, Tempst P, Nathan CF. S-nitroso proteome of Mycobacterium tuberculosis: enzymes of intermediary metabolism and antioxidant defense. Proc. Natl Acad. Sci. USA 102(2), 467-472 (2005). (Pubitemid 40116790)
74. Darwin KH, Ehrt S, Gutierrez-Ramos JC, Weich N, Nathan CF. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302(5652), 1963-1966 (2003). (Pubitemid 37523503)
75. Gold B, Deng H, Bryk R et al. Identification of a copper-binding metallothionein in pathogenic mycobacteria. Nat. Chem. Biol. 4(10), 609-616 (2008).
76. Brunori M, Forte E, Arese M, Mastronicola D, Giuffre A, Sarti P. Nitric oxide and the respiratory enzyme. Biochim. Biophys. Acta 1757(9-10), 1144-1154 (2006). (Pubitemid 44442121)
77. Cleeter MW, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AH. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 345(1), 50-54 (1994).
78. Sun Z, Zhang Y. Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber. Lung Dis. 79(5), 319-320 (1999). (Pubitemid 29479132)
79. Paramasivan CN, Kubendiran G, Herbert D. Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. Indian J. Med. Res. 108, 115-119 (1998). (Pubitemid 28479412)
80. Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43(5), 1285-1288 (1999). (Pubitemid 29214765)
81. Dhillon J, Allen BW, Hu YM, Coates ARM, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuber. Lung Dis. 2(9), 736-742 (1998). (Pubitemid 28429724)
82. Aly S, Wagner K, Keller C et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 210(3), 298-305 (2006). (Pubitemid 44660508)
83. Tsai MC, Chakravarty S, Zhu GF et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell. Microbiol. 8(2), 218-232 (2006). (Pubitemid 43356045)
84. Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis. 198(2), 275-283 (2008). (Pubitemid 352019294)
85. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole antiinfectives. Clin. Pharmacokinet. 23(5), 328-364 (1992).
86. Freeman CD, Klutman NE, Lamp KC. Metronidazole - a therapeutic review and update. Drugs 54(5), 679-708 (1997).
87. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Tinidazole in anaerobic infections - a review of its antibacterial activity, pharmacological properties and therapeutic efficacy. Drugs 24(2), 85-117 (1982). (Pubitemid 13234969)
88. Gillis JC, Wiseman LR. Secnidazole - a review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 51(4), 621-638 (1996).
89. Lamp KC, Freeman CD, Klutmam NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. 36(5), 353-373 (1999). (Pubitemid 29261511)
90. Roe FJC. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery 93(1), 158-164 (1983). (Pubitemid 13093127)
91. Roe FJC. Safety of nitroimidazoles. Scand. J. Infect. Dis. 72-81 (1985). (Pubitemid 16244190)
92. Desai CR, Heera S, Patel A, Babrekar AB, Mahashur AA, Kamat SR. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J. Assoc. Physicians India 37(11), 694-697 (1989).
93. Garton NJ, Waddell SJ, Sherratt AL et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 5(4), e75 (2008).
94. Lenaerts AJ, Gruppo V, Marietta KS et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49(6), 2294-2301 (2005). (Pubitemid 40734457)
95. Carvalho E, Francisco AP, Iley J, Rosa E. Triazene drug metabolites. Part 17: synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes. Bioorg. Med. Chem. 8(7), 1719-1725 (2000). (Pubitemid 30427237)
96. Tyagi S, Nuermberger E, Yoshimatsu T et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49(6), 2289-2293 (2005). (Pubitemid 40734456)
97. Nuermberger E, Rosenthal I, Tyagi S et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50(8), 2621-2625 (2006). (Pubitemid 44198679)
98. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemothr. 52(10), 3664-3668 (2008).
99. Nuermberger E, Tyagi S, Tasneen R et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52(4), 1522-1524 (2008). (Pubitemid 351522025)
100. Sung JC, Garcia-Contreras L, Verberkmoes JL et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob. Agents Chemother. 53(4), 1338-1343 (2009).
101. Ordway D, Palanisamy G, Henao-Tamayo M et al. The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J. Immunol. 179(4), 2532-2541 (2007).
102. Turner OC, Basaraba RJ, Orme IM. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect. Immun. 71(2), 864-871 (2003). (Pubitemid 36150782)
103. Garcia-Contreras L, Sung JC, Muttil P et al. Dry Powder PA-824 Aerosols for treatment of tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 54(4), 1436-1442 (2010).
104. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 53(9), 3720-3725 (2009).
105. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob. Agents Chemother. 53(9), 3726-3733 (2009).
106. Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J. Intern. Med. 246(3), 247-252 (1999). (Pubitemid 29426443)
107. Gisclon LG, Giacomini KM. Inhibition of cimetidine transport by creatinine in luminal membrane-vesicles prepared from rabbit kidney. Drug Metab. Dispos. 16(2), 331-332 (1988).
108. Kastrup J, Petersen P, Bartram R, Hansen JM. The effect of trimethoprim on serum creatinine. Brit. J. Urol. 57(3), 265-268 (1985). (Pubitemid 15061011)
109. Larsson R, Bodemar G, Kagedal B, Walan A. The effects of cimetidine (tagamet) on renal-function in patients with renal-failure. Acta Med. Scand. 208(1-2), 27-31 (1980). (Pubitemid 10004157)
110. Opravil M, Keusch G, Luthy R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob. Agents Chemother. 37(5), 1056-1060 (1993). (Pubitemid 23141320)
111. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54(8), 3402-3407 (2010).
112. Sirgel FA, Fourie PB, Donald PR et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 172(1), 128-135 (2005). (Pubitemid 40923325)
113. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4(9), 796-806 (2000).
114. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7), 677-686 (1999).
115. Prideaux B, Dartois V, Staab D et al. High-Sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. (2011).
116. Hurdle JG, Lee RB, Budha NR et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother. 62(5), 1037-1045 (2008).
117. Vicente E, Villar R, Burguete A et al. Efficacy of quinoxaline-2- carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob. Agents Chemother. 52(9), 3321-3326 (2008).
118. Goldman RC. Maximizing bactericidal activity with combinations of bioreduced drugs. Future Med. Chem. 2(8), 1253-1271 (2010).